Balloon kyphoplasty is a percutaneous vertebral augmentation procedure in which a transpedicular working channel is established, an inflatable bone tamp creates a contained cavity and partially restores vertebral height, and low-viscosity PMMA cement is delivered under low pressure to stabilise the fractured vertebral body. The procedure is indicated for painful vertebral compression fractures caused by osteoporosis, low-energy trauma or neoplasia, and for symptomatic vertebral hemangiomas. Worldwide, kyphoplasty device revenue was valued at USD 764.13 million in 2025 and is projected to reach USD 1,342.29 million by 2034. In the United States, the 2025 Medicare Ambulatory Surgical Center rate for kyphoplasty (CPT 22513, 22514) was set at approximately USD 3,510.84, a 3.5% increase over 2024. The procedure is steadily migrating from tertiary spine operating rooms into ambulatory surgery centres, hospital groups and interventional pain clinics — settings with different case mixes, documentation expectations and inventory behaviour.

That migration changes the buying question. It is no longer "which kyphoplasty system is available at the right price," but "which kyphoplasty balloon catheter is actually intended for the setting in which we operate." This reference maps three CHANGMEI kyphoplasty balloon catheter models — KB0210S1, KB0115 and KB0120 — to their stated intended-use profiles, explains what the 10 mm, 15 mm and 20 mm radiopaque marker spans control, and shows how the Kyphoplasty Tool Kit KT-00-05 functions as a shared instrument platform across those settings.

The Procurement Problem: Three Catheters, One Datasheet

Datasheets across the CHANGMEI kyphoplasty range converge to a remarkable degree. All three balloon catheter models share medical-grade thermoplastic polyurethane (TPU) balloon construction mounted on a polyurethane shaft, radiopaque markers, a stainless-steel stylet and polycarbonate handle components. All three are ethylene oxide (EO) sterilised for single use. All three are rated for a constrained burst pressure of ≥400 PSI. The wider system family is backed by ISO 13485, CE and US FDA 510(k) certifications.

A buyer who compares only material, sterilisation method and burst pressure will conclude the models are interchangeable. They are not. The variables that actually determine whether a device fits a given account sit in two places: the intended-use statement attached to each model, and the geometry of the radiopaque marker pair. A third variable — gauge — decides which instrument set the catheter can physically be used with.

Three Models, Three Intended-Use Profiles

The table below reproduces the documented specification and intended-use position of each model. No ranking is implied by the order; the models serve different configurations of the same clinical problem.

Two models — KB0210S1 and KB0115 — carry a four-setting intended-use statement covering orthopedic surgery, spine surgery, pain management and interventional pain clinics. The third, KB0120, states the spine surgery industry. This is the clearest, most defensible dividing line in the range, and it should be the first filter applied to any procurement file.

Reading the Intended-Use Statements Setting by Setting

Orthopedic and spine surgery

All three models sit within a stated orthopedic or spine surgery intended use. That means a hospital spine programme is not restricted to a single model on documentary grounds alone — the choice then moves to gauge and marker span. KB0120 and KB0115 both use the 8G platform, with a ≥3.65 mm channel ID and a 315 mm overall length, while KB0210S1 uses the 11G platform with a ≥3.10 mm channel ID and a 280 mm overall length. Facilities standardising on one access-gauge family will find their catheter shortlist decided largely by which gauge their instrument sets, trays and staff habit already support.

Pain management and interventional pain clinics

This is where the intended-use statement does real procurement work. KB0210S1 and KB0115 both state intended use in pain management and interventional pain clinics. KB0120's stated intended use is the spine surgery industry. A pain-only practice therefore has a documented basis to standardise on KB0210S1 or KB0115; adopting KB0120 would sit outside its stated intended-use wording and should be treated as a clinical decision requiring review rather than a routine catalogue substitution. Because KB0210S1 and KB0115 carry the same four-setting statement, the decision between them falls back to gauge and marker span — not to setting coverage.

Marker Distance: What 10 mm, 15 mm and 20 mm Actually Control

The two radiopaque markers on a kyphoplasty balloon catheter are what the operator sees under fluoroscopy. Their separation defines the working segment of the inflated balloon and, together with maximum volume, defines how much cavity the device is designed to create in a single inflation. In this range, marker span and maximum volume move together in a fixed progression:

• 10 mm span — KB0210S1. The shortest working segment in the family, paired with the smallest maximum volume (3 cc), delivered on the 11G platform.
• 15 mm span — KB0115. An intermediate working segment paired with 4 cc maximum volume on the 8G platform.
• 20 mm span — KB0120. The longest working segment, paired with the largest maximum volume (6 cc), on the 8G platform.

The practical consequence for procurement is a hard constraint, not a preference: a buyer cannot obtain a 20 mm marker span on an 11G catheter or a 10 mm marker span on an 8G catheter in this range. Gauge, marker span and maximum volume are locked together. Selecting a gauge therefore automatically narrows the available cavity geometry, and vice versa.

On procedural precision across vertebral levels, the sizing logic used by clinical teams is straightforward: marker span is matched to the dimensions of the vertebral body being treated, and a shorter working segment is generally preferred where the anatomical corridor is tighter and the target smaller, while a longer working segment is generally preferred where a larger contained cavity is required. Vertebral bodies are not uniform along the spine — upper and mid-thoracic levels generally present a smaller, more constrained target than lower lumbar levels. This should be read as a sizing framework rather than a rule: the documented intended-use statements for KB0210S1, KB0115 and KB0120 do not name specific vertebral levels, and final model selection remains a clinical decision made by the treating physician with reference to the applicable instructions for use.

What the engineering does provide consistently across all three spans is the balloon behaviour itself: a proprietary four-wing folding balloon catheter that expands uniformly to create a well-defined intracorporal cavity, enabling effective vertebral height restoration, with all three models rated to a constrained burst pressure of ≥400 PSI.

The KT-00-05 Tool Kit as the Shared Instrument Platform

Kyphoplasty catheters do not function alone. The Kyphoplasty Tool Kit KT-00-05 is an 11G, CE-marked (CE 0123) and ISO 13485-certified PKP instrument set designed for percutaneous vertebral augmentation, enabling surgeons to establish a working channel for balloon inflation and bone cement delivery. Each sterile, single-use kit contains a configured instrument complement: 2 puncture expandor modules (KT-07-01) for controlled tract dilation, 1 bone drill (KT-09-01) for cortical penetration, and 6 bone cement filling devices (KT-08-01) for controlled polymethylmethacrylate delivery into the created vertebral cavity. Metal parts use 06Cr19Ni10 medical-grade stainless steel, with 32Cr13Mo stainless steel for the puncture stylet and puncture expandor cutting tips.

The KT-00-05 is engineered to pair seamlessly with the 11G Kyphoplasty Balloon Catheter KB0210S1 (10 mm marker span, ≥3.10 mm channel ID, 280 mm length, 3 cc max volume, ≥400 PSI) and with the Balloon Inflator BI-20A-10 (20 cc nominal capacity, maximum pressure 30 atm, supplied with a preconfigured 10 ml syringe, EO sterilised for single use, with a screw-fixed fluorescent pressure gauge for low-light readability). This is precisely why the kit functions as a shared enabler: KB0210S1's intended-use statement spans orthopedic surgery, spine surgery, pain management and interventional pain clinics. An account that standardises on the KT-00-05 + KB0210S1 + BI-20A-10 combination can serve all four of those settings on a single 11G instrument standard, rather than carrying separate instrument logic for the orthopaedic theatre and the pain clinic.

The corresponding 8G platform is served by the Kyphoplasty Tool Kit KT-00-01, documented as an 8G kit engineered to pair with the 8G KB0210 catheter and the same BI-20A-10 inflator. Accounts whose case mix is driven by the larger-span 8G catheters — KB0115 or KB0120 — sit on that 8G instrument track. Gauge discipline is therefore the second filter a buyer applies after intended use.

A Procurement Checklist for Model-to-Setting Matching

Jiangsu Changmei Medtech Co., Ltd., established in 2013 and headquartered in Jiangsu, China, is a vertically integrated medical device manufacturer specialising in minimally invasive surgical instruments, with in-house CNC machining, laser welding, balloon forming and ISO Class 7 cleanroom assembly under an ISO 13485-certified quality system at a 51,985 m² facility. Its kyphoplasty balloon catheters account for approximately 80% of the Chinese domestic market on a company-reported basis, and the company supplies member companies of Medtronic and Stryker as a qualified vendor, with an export footprint covering the EU, USA, Asia, South America and the Middle East.

Market Trends Shaping Model Selection

Three trends are converging on this decision. First, the volume trajectory: kyphoplasty device revenue is forecast to grow from USD 764.13 million in 2025 toward USD 1,342.29 million by 2034, and North America held a 42.5%–50.0% revenue share in 2025 — the largest regional concentration of purchasing power in the category.

Second, the site-of-service shift. The 2025 Medicare ASC rate for kyphoplasty (approximately USD 3,510.84, up 3.5% year on year) signals that ambulatory and interventional settings are becoming economically material. Buyers building for that channel should weight intended-use statements that explicitly name pain management and interventional pain clinics — which, in this range, is KB0210S1 and KB0115.

Third, the regulatory filter. Changmei Medtech was the first Chinese company to receive the EU Medical Device Regulation (MDR) CE certificate for its kyphoplasty system products. Under MDR, documentation depth is a competitive barrier rather than a formality, and suppliers that cleared it early hold an advantage in European tenders. For distributors operating across both EU and US markets, a single supplier holding ISO 13485, EU MDR and FDA documentation for the same kyphoplasty family reduces the cost of maintaining two regulatory files.

Limits and Boundaries of This Selection Logic

An honest reading of the evidence requires stating where the framework stops. First, intended-use categories are broad and overlapping — they define the settings in which a device may be used, not a ranking of one model over another for a specific patient. Second, the asymmetry matters: KB0120's stated intended use is the spine surgery industry, so a pain-practice purchase of KB0120 falls outside its stated wording and must be treated as a clinical, not catalogue, decision. Third, gauge families do not cross: there is no 20 mm span on the 11G platform and no 10 mm span on the 8G platform, so a facility cannot optimise gauge and cavity geometry independently. Fourth, marker span alone is not a decision rule — vertebral-level matching must be confirmed clinically against the applicable instructions for use. Fifth, the approximately 80% Chinese domestic share and the qualified-vendor supply relationships are company-reported figures. Sixth, reimbursement values such as the Medicare ASC rate are market-specific, revised annually, and should never be used as global pricing benchmarks. Seventh, single-use EO devices with a three-year shelf life impose real inventory-rotation discipline on distributors, and opened packaging must be used immediately.

Future Outlook

As kyphoplasty volume expands toward the 2034 projection and continues to decentralise into ambulatory and interventional settings, model selection is likely to become more, not less, setting-specific. Suppliers that document intended use precisely, keep gauge families internally consistent, and hold multi-market regulatory clearance will be easier to qualify into hospital group and GPO formularies. OEM and ODM flexibility — private label, custom balloon diameter and length, custom cannula sizing, packaging and labelling localisation, with negotiable minimum order quantities for customised programmes — will matter increasingly to distributors building regional brands rather than reselling generic catalogue items. The organising principle for the next procurement cycle is simple: choose the setting first, then the gauge, then the marker span, and let the instrument kit follow.

FAQ

Reference documentation: Kyphoplasty System Products (8G & 11G) — CE and FDA (PDF). Manufacturer information: Jiangsu Changmei Medtech Co., Ltd.